Marble, columns and stairs
Apr 3, 2023

On April 3, 2023, an affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) completed its previously announced agreement to acquire Apotex Pharmaceutical Holdings Inc. (“Apotex”).

SK Capital is a private investment firm focused on the specialty materials, specialty chemicals and pharmaceuticals sectors. Apotex is a global pharmaceutical company that produces high-quality, affordable medicines across all major therapeutic areas for patients around the world.

Working alongside Kirkland & Ellis LLP, McMillan acted as Canadian counsel to SK Capital on this cross-border transaction. McMillan’s representation included advising on the corporate acquisition, regulatory filings, financing and a related sale-leaseback transaction in connection with this cross-border transaction.

Michael Whitcombe led the national and multidisciplinary team which included Caroline Samara, Paul Barbeau, Tess Dimroci, Rima Halabi, Charlotte Conlin (Corporate/M&A); Andrea Onn, Waël Rostom, Maria Sagan, Tushara Weerasooriya, Jeff Rogers, Christina Kim, Meagan Moulton (Financial Services); Michael Friedman, Todd Miller, Jamie Wilks (Tax); James Musgrove, Dan Edmondstone, Janine MacNeil, Joshua Chad, Beth Riley (Competition); Kari Kim-Gallately, David Ross, Kevin Chen, Shahram Khalili, Meghan Schwan, Samantha Irving (Real Estate); Robert Piasentin, Yue Fei (Technology); Peter Giddens (Intellectual Property); Kristen Pennington (Privacy); Ralph Cuervo-Lorens, Talia Gordner (Environmental); and Paul Boshyk (Employment & Labour).

As a national business law firm with exceptional capabilities to lead businesses through cross-border transactions and investments into Canada and within multifaceted regulatory regimes, McMillan provides real-time business solutions to our clients. Our legal teams are skilled at structuring and closing complex deals of all shapes and sizes in Canada, the US and internationally and in providing innovative transactional advice and solutions. Our understanding of business imperatives and our relationships with the regulators helps our clients stay ahead.